Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Top Cited Papers
Open Access
- 3 December 2009
- Vol. 339 (dec03 1), b4731
- https://doi.org/10.1136/bmj.b4731
Abstract
Objective To investigate the risk of incident myocardial infarction, congestive heart failure, and all cause mortality associated with prescription of oral antidiabetes drugs. Design Retrospective cohort study. Setting UK general practice research database, 1990-2005. Participants 91 521 people with diabetes. Main outcome measures Incident myocardial infarction, congestive heart failure, and all cause mortality. Person time intervals for drug treatment were categorised by drug class, excluding non-drug intervals and intervals for insulin. Results 3588 incident cases of myocardial infarction, 6900 of congestive heart failure, and 18 548 deaths occurred. Compared with metformin, monotherapy with first or second generation sulphonylureas was associated with a significant 24% to 61% excess risk for all cause mortality (PConclusions Our findings suggest a relatively unfavourable risk profile of sulphonylureas compared with metformin for all outcomes examined. Pioglitazone was associated with reduced all cause mortality compared with metformin. Pioglitazone also had a favourable risk profile compared with rosiglitazone; although this requires replication in other studies, it may have implications for prescribing within this class of drugs.This publication has 42 references indexed in Scilit:
- Pharmacological Differences of Glitazones: Does Peroxisome Proliferator-Activated Receptor-α Activation Make the Difference?Journal of the American College of Cardiology, 2008
- The Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-α–Dependent Manner In Vitro and In Vivo in MiceJournal of the American College of Cardiology, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- PROactive: time for a critical appraisalEuropean Heart Journal, 2008
- Coronary heart disease outcomes in patients receiving antidiabetic agentsPharmacoepidemiology and Drug Safety, 2007
- The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapyPharmacoepidemiology and Drug Safety, 2007
- Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort studyCMAJ : Canadian Medical Association Journal, 2006
- Do sulfonylurea drugs increase the risk of cardiac events?CMAJ : Canadian Medical Association Journal, 2006
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998